Page 2 - Immvira Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immvira pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immvira Pharma Today - Breaking & Trending Today

ImmVira clinical snapshot: Intratumoral injected OV (MVR-T3011 IT) monotherapy achieved ORR of 25% on late-stage HNC patients, indicating significant advantage over SOC and PD-1 treatment

/PRNewswire/ Following the recent publication of efficacy data on advanced melanoma, ImmVira s intratumoral injected OV product MVR-T3011 IT has also shown. ....

Objective Response Rate , Progression Free Survival , Disease Control Rate , Overall Survival ,

ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma

/PRNewswire/ ImmVira s first intratumoral injected OV product MVR-T3011 IT has shown positive efficacy in the course of clinical studies in the U.S. and. ....

United States , Prnewswire Immvira ,

ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round

/PRNewswire/ ImmVira announced its successful signing of Series-C+ financing transaction documents with the first batch of investors recently. This round of. ....

United States , Prnewswire Immvira , China Merchants Direct Investments , China Resources Biopharmaceutical Co Ltd , Unifortune Group , China Merchants Direct Investments Limited , Grace Zhou , Health Care Amp Hospitals , Pharmaceuticals , Medical Pharmaceuticals , Venture Capital ,

ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation

/PRNewswire/ On August 1, 2022, U.S. time, ImmVira s brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has. ....

United States , Immvira Ov , Guoying Zhou , Drug Administration , Malignant Glioma , Orphan Drug Designation , Orphan Drug Act , Grace Guoying Zhou ,

ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities

/PRNewswire/ ImmVira s global first intravenous ("IV") administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed the first. ....

United States , Prnewswire Immvira , Stable Disease ,